Business Context and Reporting Period
This Form 8-K was filed by Abbott Laboratories on January 24, 2017. The report details the completion of the acquisition of St. Jude Medical, Inc. on January 4, 2017, and outlines the new reporting structure for the Abbott Cardiovascular and Neuromodulation (ACN) business effective for the first quarter of 2017.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. It references Exhibit 99.1 for comparable revenue data by product category for the first nine months of 2016, but the specific numerical values are not included in the text of this report.
Material Changes
- Acquisition Completion: Abbott Laboratories finalized the acquisition of St. Jude Medical, Inc. on January 4, 2017.
- Segment Restructuring: The ACN business now combines Abbott's historical Vascular Products segment with St. Jude Medical's businesses.
- New Reporting Categories: ACN sales will be reported under three new categories:
- Rhythm Management and Heart Failure: Includes pacemakers, ICDs, cardiac resynchronization therapy, ventricular assist devices, and the CardioMEMS HF system.
- Cardiovascular and Structural Heart: Includes coronary and endovascular devices, diagnostic imaging, heart pumps, and heart valve replacement/repair devices.
- Neuromodulation: Includes spinal cord stimulation, dorsal root ganglion stimulation, and deep brain stimulation products.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard legal disclaimer. The report explicitly states that the information contained herein is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific revenue figures for the first nine months of 2016 by reviewing Exhibit 99.1, which is referenced but not detailed in this text.
- Confirm the integration timeline and operational synergies expected from the St. Jude Medical acquisition in subsequent quarterly reports.
- Monitor future filings for the first full quarter of 2017 to observe the initial financial impact of the new ACN reporting structure.